Cambrex to acquire CDMO Halo Pharma for $425 million

摘要

Cambrex (East Rutherford, New Jersey) has reached agreement to acquire Halo Pharma (Whippany, New Jersey) for approximately $425 million in cash. Halo is a contract development and manufacturing organization (CDMO) that is majority-owned by funds managed by the private equity firm SK Capital Partners (New York). The acquisition will enable Cambrex to enter the large and growing CDMO market for finished dosage forms. Halo's core competencies include developing and producing complex and difficult to produce formulations, and controlled substances, according to Cambrex.